Friday, July 30, 2010

Admissions Open

P.T.U Courses:

Admissions Open for B.Sc /M.Sc/PGD in Bioinformatics & Biotechnology.


For Further Details Please Contact:

Phone No: 0120-4320801\802

Mob: 09810535368, 09818473366

E-mail: info@bii.in,Visit us: www.bii.in


Saturday, July 10, 2010

Collagen manufactured from transgenic tobacco plants has great commercial promise for Hebrew University
A scientist at the Hebrew University of Jerusalem’s Robert H. Smith Faculty of Agriculture, Food and Environment has succeeded in producing a replica of human collagen from tobacco plants – an achievement with tremendous commercial implications for use in a variety of human medical procedures. Natural human type I collagen is the most abundant protein in the human body and is the main protein found in all connective tissue. Commercially produced collagen (pro-collagen) is used in surgical implants and many wound healing devices in regenerative medicine.
The current market for collagen-based medical devices in orthopedics and wound healing exceeds US $30 billion annually worldwide. Currently, commercial collagen is produced from farm animals such as cows and pigs as well as from human cadavers. These materials are prone to harbor human pathogens such as viruses or prions (mad-cow disease). Human cadaver is scarce, and for certain indications possesses serious ethical issues. Producing human recombinant type I pro-collagen requires the coordinated expression of five different genes. Prof. Oded Shoseyov of the Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture has established the only laboratory in the world that has reported successful co-expression all the five essential genes in transgenic tobacco plants for the production of processed pro-collagen. For this work, Shoseyov was one of the recipients of a Kaye Innovation Award during the Hebrew University Board of Governors meeting in June. Shoseyov’s invention on has been patented, and the scientific findings behind it were published recently in the journal Biomacromolecules.
A company, CollPlant Ltd., has been established based on patents and technology that were developed in Shoseyov’s laboratory. It has raised US$15 million to establish the first commercial molecular farming company in Israel and is already manufacturing collagen-based products that have attracted collaborative commercial interest from companies in the US, Japan Europe and Israel. Yissum, the technology transfer company of the Hebrew University, is one of the shareholders of CollPlant. CollPlant is a public company traded in “TASE”, and the potential revenue for the Hebrew University from this invention is estimated to reach into the multi-million dollar range. The Kaye Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.

Friday, July 2, 2010

Genes? It's complicated
The advance heralded a decade ago in mapping human DNA is yet to lead to the answers we craved
Ten years ago the $10bn Human Genome Project announced it had completed the first draft of the blueprint for human life. It was hailed as a huge scientific advance, comparable to putting a man on the moon. President Bill Clinton declared: "We'll go from knowing almost nothing about how our genes work to enlisting genes in the struggle to prevent and cure illness. This will be the scientific breakthrough of the century, perhaps of all time."
The project at last laid bare the entire human genetic code – 22,000 or so genes (the precise number is still uncertain) – that make us into the people we are. Several decades of research into the cause of diseases before the project had firmly identified genes as a significant cause of many important diseases.

The first haul of genetic diseases was of those fairly rare but devastating inherited diseases, such as cystic fibrosis and haemophilia, that are caused by single genes. Most of the genes responsible for those had been fished out of the genome long before the sequencing project hauled in its net. But the project was expected to find genes for various far more common conditions, such as cancer, diabetes, heart disease, autism, depression and schizophrenia, because most of these conditions tend to run in families. Studies of families in which these diseases were common, particularly of twins, had established a level of heritability for each condition, and the levels were high. Autism comes out at a whopping 90%, indicating that most autism is caused by faulty genes (and certainly not by faulty vaccines). The heritability of schizophrenia was about 80% whereas conditions such as heart disease, diabetes and cancer came in anywhere between 30% and 70%.

And it wasn't just diseases that were caused by genes. Many behavioural studies indicated that intelligence, personality, sexual orientation and even voting preference seemed to be highly heritable. If genes were so powerful, it should be straightforward to identify the culprits in the genome.

But a decade later these expectations have not been fulfilled. The project that promised so much has, so far, delivered very little. Very few genes have been found that account for more than 1% of the risk of any of those common diseases. And even the most significant intelligence gene yet found is responsible for variation in individual intelligence equivalent to less than one IQ point. The scientists who went in search of whoppers netted only a host of minnows. Where are the missing genes?

Like most things in life, it turns out that genes are more complex than we thought. Those genes responsible for single-gene defects such as cystic fibrosis and haemophilia are the low-hanging fruit. Common diseases, and such attributes as intelligence, are not caused by single genes or even handfuls of genes, but probably by networks of hundreds or even thousands of genes.

To understand these networks, we need to look, not at the branches, but at the roots of the genetic tree. Genes form tangles of interactions with each other such that the effect of chopping one or another is unpredictable and depends on the connectivity of the whole network. Finding a gene responsible for a disease is mostly like finding a root responsible for maintaining a tree.

The task of unravelling the roots of biology is the new science of system biology, in which biologists work with mathematicians and computer scientists to build models of complex networks. This is where the causes of heart disease, diabetes and autism are now being sought. To paraphrase Winston Churchill, the genome project was not the end. It was not even the beginning of the end. But it was, perhaps, the end of the beginning in the search for our genes.

Latest Pharma - Biotech Jobs

Latest Intellectual Property Jobs

Latest Biotechnology Jobs

BII Blog helps in dissemination of information and knowledge